



Meeting Schedule (All times listed are in Eastern Standard Time)

SATURDAY, MARCH 1, 2025 - CME 8.50

10:00 AM - 10:02 AM	<p>Opening Remarks</p> <p><i>Gregory Gardner, MD, University of Washington, AMPC Chair</i> <i>Elizabeth Volkman, MD, MS, University of California, Los Angeles, AMPC Clinical Chair</i></p>
10:02 AM - 11:28 AM	<p>Rheumatoid Arthritis-Associated Interstitial Lung Disease: Advances in Screening, Diagnosis and Patient Phenotyping</p> <p>This session will have three 20-minute presentations that cover distinct aspects of Rheumatoid Arthritis-Associated-Interstitial Lung Disease (RA-ILD) from early identification of ILD through HRCT text mining, to phenotyping patients through biomarker analyses of BAL fluid. The third lecture will cover how capillaroscopy may be used to identify patients with RA at risk for ILD who should be referred for screening. ILD is underdiagnosed in RA and often diagnosed at a late-disease stage. At the conclusion of this session, the audience will gain a better understanding of: (1) how to identify patients with RA at highest risk for ILD; (2) how to apply precision medicine to risk stratify patients; (3) how novel imaging methods accessible to the rheumatologist (e.g., capillaroscopy) could be used to improve the early identification of ILD in RA.</p> <p>Learning Objectives</p> <ul style="list-style-type: none"> • Devise risk stratification approaches to identify ILD in patients with RA • Distinguish RA-ILD phenotypes that can inform treatment decisions • Assess novel imaging methods accessible to the rheumatologist (e.g., capillaroscopy) that may improve the early identification of ILD in RA <p>Moderator <i>Samuel Good, MD, University of California, Los Angeles</i></p> <p>Speakers <i>Bryant England, MD, PhD, University of Nebraska Medical Center</i> <i>Scott Matson, MD, University of Kansas</i> <i>Vanessa Smith, MD, PhD, Ghent University Hospital</i></p>
11:28 AM - 11:45 AM	<p>Q&A Session with Presenters</p> <p><i>Bryant England, MD, PhD, University of Nebraska Medical Center</i> <i>Scott Matson, MD, University of Kansas</i> <i>Vanessa Smith, MD, PhD, Ghent University Hospital</i></p>
11:45 AM - 11:55 AM	<p>Break</p>

11:55 AM - 1:00 PM

AI: The Next Breakthrough in Documentation for Rheumatology

Artificial intelligence (AI) is rapidly transforming our work and lifestyle. Despite its recent surge in popularity, its early forms like speech-to-text and predictive analysis have been utilized in the healthcare industry for years. If you're using voice commands on your phone for care documentation or storing common phrases, you're already harnessing the power of AI.

Ambient listening technology is the latest exciting AI enhancement for documentation efficiency that works by capturing natural conversations between providers and patients, producing a completely tech-generated SOAP narrative within minutes. Such solutions have been proven to save providers significant time, have high accuracy rates, and are secure. An ambient listening solution can improve the connection between the provider and patient by allowing uninterrupted connections to form, while maintaining documentation quality. With ambient listening, providers can simplify their after-visit workload, going from documenting every detail from memory to simply verifying encounter details. Join us to explore how ambient listening technology works, how it has been implemented into two types of rheumatology clinical settings, and best practices.

Learning Objectives

- Recall how ambient listening works for clinical documentation in a rheumatology clinic
- Discuss the process of implementing ambient listening at an academic institution
- Discuss the process and experience of implementing ambient listening into clinical practice from a rheumatologist in an independent practice
- List benefits and challenges of incorporating ambient listening in a rheumatology clinic

Moderators

Puja Chitkara, MD, CARE

Speakers

Arinola Dada, MD, FACR, Overlake Arthritis and Osteoporosis center

Michael Pfeffer, MD, FACP, Stanford Medicine

1:00 PM - 1:15 PM

Q&A Session with Presenters

Arinola Dada, MD, FACR, Overlake Arthritis and Osteoporosis center

Michael Pfeffer, MD, FACP, Stanford Medicine

1:15 PM - 1:35 PM

20-minute Break to Collect Lunch

1:37 PM - 2:39 PM

Anti-MDA5 Juvenile Dermatomyositis: Clinical Presentation and Treatment

Juvenile dermatomyositis is a rare, autoimmune illness associated with muscle weakness and typical rashes. Anti-MDA5 has some distinct features, including increased ulceration and less muscle involvement. Some may also have rapidly progressive interstitial lung disease, associated with increased mortality. Treatment for this myositis-specific autoantibody group within juvenile dermatomyositis can be distinct. The goal of this session will be to review the current state of knowledge regarding the clinical presentation and treatment/management of anti-MDA5 juvenile dermatomyositis.

Learning Objectives

- Describe the presentation and clinical characteristics of anti-MDA5 juvenile dermatomyositis
- Describe clinical disease prognosis with anti-MDA5 juvenile dermatomyositis
- Discuss current treatment of anti-MDA5 juvenile dermatomyositis, including distinct features such as interstitial lung disease

Moderators

Sara Sabbagh, DO, Medical College of Wisconsin

Belina Yi, DO, Johns Hopkins University School of Medicine

Speakers

Lisa Rider, MD, NIEHS, NIH (Not Participating)

Takayuki Kishi, MD, PhD, Tokyo Women's Medical University (Not Participating)

2:40 PM - 2:55 PM

Q&A Session

Susan Sheno, MBBS, MS, RhMSUS, Seattle Children's Hospital

2:55 PM - 3:00 PM

Break

3:00 PM - 4:02 PM

Are We Putting the CAR-T Before the Horse?

This session will update attendees on cellular therapies in systemic autoimmune diseases, including CAR-T. The attendee should be able to determine what data is needed before cellular therapies can be widely adopted.

Learning Objectives

- Describe cellular therapies with respect to autoimmune disease treatment
- Appraise the rationale and logistics of cellular therapy
- Discuss future trials and their design

Moderators

Saira Sheikh, MD, Linda Coley Sewell Distinguished Professor of Medicine
University of North Carolina at Chapel Hill

Roberto Caricchio, MD, Professor of Medicine, Chief of the Division of Rheumatology
University of Massachusetts Chan Medical School

Speakers

Anca Askanase, MD, MPH, Director, Columbia University Medical Center
George Tsokos, MD, BIDMC

4:02 PM - 4:17 PM

Q&A Session with Presenters

Anca Askanase, MD, MPH, Director, Columbia University Medical Center
George Tsakos, MD, BIDMC

4:18 PM - 5:43 PM

Optimizing the Management of Skin Disease in Systemic Sclerosis: Using Clinical Features and Novel Disease Activity Measures to Guide Treatment Decisions

Systemic sclerosis (SSc) is a heterogeneous disease with variability in skin involvement. The goal of this session is to provide an update on the use of SSc clinical features and imaging that can guide providers on appropriate skin management. The role of autologous stem cell transplant for treatment of skin disease will be discussed.

Learning Objectives

- Combine clinical features, such as disease duration, autoantibody profiles, and comorbidities, to develop skin-targeted treatment decisions in systemic sclerosis (SSc)
- Evaluate assessment tools to quantify skin disease activity in early SSc
- Debate when to intervene with autologous stem cell transplantation for skin disease in SSc

Moderators

Arisa Young, MD, UCLA
Rachel Wallwork, MD, MHS, Johns Hopkins University

Speakers

Robyn Domsic, MD, MPH, University of Pittsburgh
Madelon Vonk, MD, PhD, Radboud University Nijmegen Medical Centre
Ankoor Shah, MD, Duke University

5:43 PM - 6:00 PM

Q&A Session with Presenters

Robyn Domsic, MD, MPH, University of Pittsburgh
Madelon Vonk, MD, PhD, Radboud University Nijmegen Medical Centre
Ankoor Shah, MD, Duke University

6:00 PM - 6:05 PM

Break

6:05 PM - 7:05 PM **Year in Review**

This session will cover recent discoveries in the last 12 months from the basic science literature that are relevant to Rheumatology.

Learning Objectives

- Learn about new clinical discoveries pertinent to rheumatic disease
- Become familiar with new basic science discoveries pertinent to rheumatic disease

Moderators

Annie Davidson, MBBS, FRACP, *Feinstein Institutes for Medical Research*

Tracy Frech, MD, MS, *Vanderbilt University Medical Center*

Speakers

Michael Pillinger, MD, *New York University Grossman School of Medicine*

S. Louis Bridges, MD, PhD, *Hospital for Special Surgery*

7:05 PM - 7:14 PM **Q&A Session with Presenters**

Michael Pillinger, MD, *New York University Grossman School of Medicine*

S. Louis Bridges, MD, PhD, *Hospital for Special Surgery*

7:14 PM - 7:15 PM **Final Comments**